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GP IIb/IIIa-antagonistsBackground: IABP is routinely used to support coronary blood ﬂow and systemic circulation in patients with car-
diogenic shock. Our aimwas to explore the incidence of vascular complications associatedwith the use of IABP in
this scenario and their inﬂuence on mortality.
Methods: Thereforwe analysed 204 consecutive patients between 2002 and 2013 treatedwith IAPB in cardiogen-
ic shock for vascular complications and mortality within 30 days after implantation of IAPB. Primary endpoints
were severe bleeding (TIMI-deﬁnition: intracranial bleeding, loss of haemoglobin (Hb) N5 g/dl or haematocrit
(PCV) N15%), vascular complications with therapeutic consequence (venous thrombosis, arterial embolism)
and stroke.
Results: 80 (39%) patients died within 30 days after implantation of IABP. In 42 (21%) patients, vascular compli-
cations occurred: severe bleeding was present in 26 patients (62% of all complications), 13 (31%) patients suf-
fered from venous thrombosis or arterial embolism and 3 (7%) patients from stroke. 25% of the patients who
died had a vascular complication. The rate in patients who overcame cardiogenic shock was 17.7% (p= 0.22).
Multivariate analyses showed treatmentwith Glycoprotein (GP) IIb/IIIa- inhibitors to be an independent risk fac-
tor for the occurrence of vascular complications (p= 0.04).
Conclusion: Vascular eventswith the use of IABP are common but in our study, not signiﬁcantly associatedwith a
higher mortality. Treatment with GP IIb/IIIa-antagonists is associated with a higher risk of vascular events.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The mortality of patients with cardiogenic shock complicating acute
myocardial infarction is in the face of early revascularization by percuta-
neous coronary intervention still very high (40–50%) [1–4]. First clini-
cally introduced in 1968, intraaortic balloon pump (IABP) is the most
commonly used procedure for mechanical hemodynamic support in
this scenario [5,6]. In the past, clinical and experimental studies sug-
gested a hemodynamic beneﬁt due to afterload reduction and improve-
ment of coronary diastolic blood pressure [7]. Earlier studies – also
recent ones – showed no reduction in cardiovascular mortality with
the use of IABP [8,9]. Nevertheless, the existing American (ACC/AHA)
and European (ESC) guidelines recommend the use of IABP in patients
with cardiogenic shock (class IB and class IC recommendation)
[10–12]. A recentmeta-analysis alreadyquestioned these recommenda-
tions as they couldn't prove any mortality beneﬁt of IABP in patients
with ST-segment elevation myocardial infarction (STEMI) complicated
by cardiogenic shock and treated with primary percutaneous coronaryr).
eliability and freedom from bias
. This is an open access article underintervention (PCI) [13]. Beside these deﬂating facts, they also showed
an increase in major bleeding and stroke. Therefore, we aimed to inves-
tigate the frequency of vascular events associatedwith the use of IABP in
patients suffering from cardiogenic shock.2. Methods
We analysed 204 consecutive patients between 2002 and 2013 with
IAPB treatment in cardiogenic shock for vascular complications andmor-
tality within 30 days after IABP implantation. Cardiogenic shock was de-
ﬁned as systolic blood pressure b90 mmHg, heart rate N100 bpm, and
clinical signs of organic hypoperfusion. Primary endpoints were severe
bleeding (TIMI-deﬁnition: intracranial bleeding, loss of haemoglobin
(Hb) N5 g/dl or haematocrit (PCV) N15% [14]), vascular complications
with therapeutic consequence (venous thrombosis, arterial embolism)
and stroke. The analyses were performed using Graph Pad Prism Version
5.01 (Graph Pad Software, San Diego, California, USA), PASW statistics
Version 18 (SPSS, Inc., an IBM Company, Chicago, Illinois, USA) and
Microsoft Excel 2010. p values b0.05 were regarded as signiﬁcant. Per-
centages were used to describe patient populations. Sex, weight, STEMI
and use of Glycoprotein (GP) IIb/IIIa-antagonists were analysed as inde-
pendent predictors of inhospital mortality and complications using athe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Vascular complications.
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tion group was analysed by multivariate binary logistic regression to
search for independent predictors of severe bleeding, vascular complica-
tions and stroke including the same values mentioned before. STEMI
was diagnosed in the presence of ST-segment elevation of 1 mm in ≥2
standard leads or ≥2 mm in ≥2 contiguous precordial leads or the pres-
ence of a left bundle branch block.
3. Results
133 of the 204 patients were male (65.2%), the mean age was 65 ±
15 years (Table 1). 171 (83.8.%) patients had a STEMI. 80 (39%) patients
died within 30 days after implantation of IABP. 105 (51.5%) patients re-
ceived GP IIb/IIIa-antagonists. In 42 (21%) patients, vascular complica-
tions occurred. Severe bleeding was present in 26 patients (62% of all
complications), 13 (31%) patients suffered from venous thrombosis or
arterial embolismand 3 (7%) patients from stroke (Fig. 1). 25% of the pa-
tients who died showed a vascular complication, the rate in patients
who survived cardiogenic shock was 17.7% (p = 0.22, Table 2, Fig. 2).
Age (67 ± 14 vs. 65 ± 13 years), female gender (36 vs. 34%) and body
weight (79.8±11.8 vs. 77.1± 12 kg)were quite similar in both groups.
Multivariate analyses showed treatment with GP IIb/IIIa-antagonists to
be an independent risk factor for the occurrence of vascular complica-
tions (p= 0.04).
4. Discussion
Early revascularization by percutaneous coronary intervention is the
main therapy strategy in patientswith acutemyocardial infarction com-
plicated by cardiogenic shock. Nevertheless, the mortality remains very
high [1–4,15–18]. Since its development in the 1960s, IABP is still the
most commonly used left ventricular assist device in these patients [6,
7,19]. Whilst current American (ACC/AHA) and European (ESC) guide-
lines recommend the use of IABP in patients with cardiogenic shock
(class IB and class IC recommendation), recent and earlier studies
showed no reduction in cardiovascular mortality when using IABP
[8–12]. Despite the potential haemodynamic effects by the increase of
coronary blood ﬂow and the reduction in myocardial oxygen demand,
the use of IABP is associated with complications such as major bleed-
ings, local and systemic infections, stroke and vascular complications
[7,20–22]. The aim of our analysis with a suitable cohort of patients
treated with IAPB in cardiogenic shock was to investigate the incidence
of vascular complications associated with the use of IABP and its
inﬂuence onmortality. Although a remarkable number of vascular com-
plications occurred, it was not signiﬁcantly associated with a higher
mortality (Figs. 1 and 2). Despite this observation in patients with se-
vere comorbidities, vascular complications potentially affect the clinical
outcome. Furthermore, bleeding complications and following transfu-
sions trigger the shock spiral [23]. Although in the past techniques for
sheathless insertion and catheters with smaller diameter wereTable 1
Baseline characteristics of the patients.
Characteristics N = 204
Age — yr 65 ± 15
Sex — no. (%)
–Male 133 (65.2)
–Female 71 (34.8)
Weight — kg 79.3 ± 11.9
Cardiovascular risk factors — no. (%)
–Current smoking 70 (34.3)
–Hypertension 143 (70.1)
–Diabetes mellitus 66 (32.4)
–Hypercholesterolemia 79 (38.7)
STEMI — no. (%) 171 (83.3)
GP IIb/IIIa-antagonists — no. (%) 105 (51.5)
Death — no. (%) 80 (39.2)developed to reduce these complications, none of them could show
any clinical beneﬁt [24]. The total mortality in our cohort 30 days after
implantation of IABP was quite similar to earlier studies, especially to
the recently published IABP-Shock II trial [8]. As reported by Zeymar
et al. with the results of the ALKK-PCI registry, we observed a similar
trend ofmore patients treatedwith GP IIb/IIIa-antagonists after implan-
tation of IABP [9]. We showed that treatment with GP IIb/IIIa-antago-
nists in combination with IABP seems to be an independent risk factor
for the occurrence of vascular complications (p= 0.04). Due to our ob-
servations, we highly recommend, like other studies before, a strict indi-
cation for the use of IABP in cardiogenic shock. The German guidelines
already deﬁne the use of IABP in patients treated by early revasculariza-
tion despite lacking evidence [25].5. Study limitations
Despite the respectable number of patients incorporated in our
study, multivariate techniques normally need a really large sample of
data to get meaningful results. We did not differentiate between the
several types of GP IIb/IIIa-antagonists in our analysis. Therefore, we
can't make a statement on signiﬁcant differences for vascular complica-
tions between them.6. Conclusion
We analysed 204 patients with cardiogenic shock and treated
with IABP for vascular complications. As seen before vascular events
are common in this setting, however, in our study not signiﬁcantly
associated with a higher mortality. An additional treatment with
GP IIb/IIIa-antagonists is associated with a higher risk of vascular
events.Conﬂicts of interest
There are no potential conﬂicts of interest, including related consul-
tancies, shareholdings and funding grants.Table 2
Patients with complications.
Complications p value
Sex
–Male vs. female no./total no. (%) 26/133 (19.5) vs. 16/71
(22.5)
0.72
STEMI vs. NSTEMI no./total no. (%) 36/171 (21) vs. 6/33 (18.3) 0.82
GP IIb/IIIa vs. no GP IIb/IIIa no./total no. (%) 30/105 (28.6) vs. 12/99
(12.1)
0.0052
Death vs. alive no./total no. (%) 20/80 (25) vs. 22/124
(17.7.)
0.22
Fig. 2. Vascular complications and death.
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